Tarık Esen1, Mert Kılıç2, Hülya Seymen3, Ömer Acar4, Mehmet Onur Demirkol5. 1. Department of Urology, VKF American Hospital, Istanbul, Turkey; Department of Urology, School of Medicine, Koç University, Istanbul, Turkey. Electronic address: tesen@ku.edu.tr. 2. Department of Urology, VKF American Hospital, Istanbul, Turkey. 3. Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Koc University, Istanbul, Turkey. 4. Department of Urology, School of Medicine, Koç University, Istanbul, Turkey. 5. Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Koc University, Istanbul, Turkey; Department of Nuclear Medicine and Molecular Imaging, VKF American Hospital, Istanbul, Turkey.
Abstract
Imaging is critical for primary staging of prostate cancer. Traditional imaging modalities (computerized tomography scan and nuclear medicine bone scans) are limited by their suboptimal diagnostic performance. Recent meta-analyses have demonstrated that nuclear imaging with 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA) using positron emission tomography/computed tomography (PET/CT) has higher sensitivity and specificity in this setting compared to conventional imaging techniques. 68Ga-PSMA PET/CT for whole-body assessment can be used as the sole imaging modality for primary lymph node and bone staging of prostate cancer. PATIENT SUMMARY: There is a rapidly growing body of evidence that nuclear imaging with 68Ga-labeled prostate-specific membrane antigen ligand using positron emission tomography/computed tomography has a higher detection rate for lymph node and bone metastases in prostate cancer patients. This approach has strong potential to replace conventional techniques in the primary setting in the near future.
Imaging is critical for primary staging of prostate cancer. Traditional imaging modalities (computerized tomography scan and nuclear medicine bone scans) are limited by their suboptimal diagnostic performance. Recent meta-analyses have demonstrated that nuclear imaging with 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA) using positron emission tomography/computed tomography (PET/CT) has higher sensitivity and specificity in this setting compared to conventional imaging techniques. 68Ga-PSMA PET/CT for whole-body assessment can be used as the sole imaging modality for primary lymph node and bone staging of prostate cancer. PATIENT SUMMARY: There is a rapidly growing body of evidence that nuclear imaging with 68Ga-labeled prostate-specific membrane antigen ligand using positron emission tomography/computed tomography has a higher detection rate for lymph node and bone metastases in prostate cancerpatients. This approach has strong potential to replace conventional techniques in the primary setting in the near future.
Authors: J Kopp; D Kopp; E Bernhardt; L Manka; A Beck; H Gerullis; P Karakiewicz; W Schoerner; P Hammerer; Jonas Schiffmann Journal: World J Urol Date: 2020-02-26 Impact factor: 4.226
Authors: João P Lima; João Carvalho; Vasco Quaresma; Edgar Tavares-da-Silva; Rodolfo Silva; Paulo Azinhais; Gracinda Costa; Arnaldo Figueiredo Journal: Res Rep Urol Date: 2021-07-07